List of Excipients in Branded Drug AUGTYRO
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| ER Squibb & Sons LLC | AUGTYRO | repotrectinib | 0003-4040 | CELLULOSE, MICROCRYSTALLINE | 2036-07-05 |
| ER Squibb & Sons LLC | AUGTYRO | repotrectinib | 0003-4040 | CROSCARMELLOSE SODIUM | 2036-07-05 |
| ER Squibb & Sons LLC | AUGTYRO | repotrectinib | 0003-4040 | SILICON DIOXIDE | 2036-07-05 |
| ER Squibb & Sons LLC | AUGTYRO | repotrectinib | 0003-4040 | SODIUM LAURYL SULFATE | 2036-07-05 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
AUGTYRO Excipient Strategy and Commercial Opportunities for Repotrectinib
AUGTYRO is an oral repotrectinib product marketed by Bristol Myers Squibb for ROS1-positive locally advanced or metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumors. Its current commercial formulation is a hard capsule containing a conventional immediate-release powder blend. The excipient opportunity is therefore concentrated in three areas: pediatric and swallowing-friendly dosage forms, bioavailability and dose-flexibility improvements, and supply-chain alternatives for commodity excipients.
The formulation has a relatively low technical barrier because it uses established oral solid-dose excipients. A competing product could potentially use the same excipient classes without infringing formulation claims, provided it meets quality, bioequivalence, stability, and regulatory requirements. The greater barriers are repotrectinib substance patents, regulatory exclusivity, clinical development requirements, and the need to reproduce exposure across a drug with a complex dose-escalation regimen.
What excipients are used in AUGTYRO capsules?
AUGTYRO capsules contain repotrectinib and a conventional excipient system consisting of lactose monohydrate, microcrystalline cellulose, sodium lauryl sulfate, colloidal silicon dioxide, and magnesium stearate. The capsule shell and printing components use standard pharmaceutical capsule materials and inks. Exact product composition is listed in the FDA prescribing information and product labeling.[1]
| Formulation attribute | AUGTYRO profile |
|---|---|
| Active ingredient | Repotrectinib |
| Dosage form | Oral hard capsule |
| Strengths | 40 mg and 160 mg |
| Release type | Immediate release |
| Core excipients | Lactose monohydrate, microcrystalline cellulose, sodium lauryl sulfate, colloidal silicon dioxide, magnesium stearate |
| Primary function | Powder dilution, flow, lubrication, wetting, and manufacturing consistency |
| Administration | Oral, with or without food |
| Commercial sponsor | Bristol Myers Squibb |
| FDA application | NDA 217664 |
The excipient system is commercially familiar. Lactose and microcrystalline cellulose provide bulk and compressibility or powder-volume control. Sodium lauryl sulfate can improve wetting and dispersion of the active ingredient. Colloidal silicon dioxide supports powder flow. Magnesium stearate reduces adhesion during capsule filling.
The formulation does not indicate a dependence on a specialized lipid system, amorphous solid dispersion, modified-release polymer, or complex solubilizing technology. That lowers the formulation-development barrier for generic or alternative-product manufacturers, although it does not remove API, patent, or regulatory barriers.
How does the AUGTYRO formulation affect excipient strategy?
The principal formulation question is whether repotrectinib requires enhanced solubility or whether the marketed product achieves adequate exposure through particle-size and powder-processing controls. Repotrectinib is a potent kinase inhibitor administered at relatively low capsule strengths, which allows a substantial proportion of the dosage unit to consist of excipients.
A practical excipient strategy would focus on:
- Consistent powder flow at the 40 mg strength.
- Dose proportionality between 40 mg and 160 mg capsules.
- Rapid disintegration and dispersion.
- Low variability in dissolution across manufacturing sites.
- Avoidance of excipients that alter CYP3A-mediated drug disposition.
- Compatibility with capsule filling at commercial scale.
Repotrectinib is metabolized primarily through CYP3A pathways and has clinically important drug-interaction risks. The excipient system should not introduce absorption enhancers, botanical components, or highly variable surfactant loads that complicate interpretation of pharmacokinetic results. The FDA label warns against strong or moderate CYP3A inhibitors and inducers, and against certain transporter-related interactions.[1]
High-value excipient development targets
| Development target | Commercial rationale | Technical risk |
|---|---|---|
| Lactose-free filler system | Expands use for patients avoiding lactose and simplifies positioning in selected markets | May change flow, fill weight, and dissolution |
| Mannitol or dibasic calcium phosphate replacement | Supports differentiated product and improved moisture control | Requires compatibility and bioequivalence work |
| Crospovidone or croscarmellose sodium | May accelerate disintegration and reduce dissolution variability | Could alter release profile |
| Alternative surfactant system | May improve wetting for poorly dispersible API | Potential PK and impurity concerns |
| Sprinkle capsule or multiparticulate formulation | Addresses swallowing difficulty and pediatric administration | Higher regulatory and manufacturing burden |
| Low-moisture formulation | Improves stability in humid markets | May increase capsule brittleness or electrostatic behavior |
| Smaller capsule architecture | Improves administration for patients with dysphagia | May require higher drug loading or a different blend |
The strongest near-term opportunity is not a radically new excipient. It is a more patient-friendly dosage form that preserves the exposure profile of the existing capsule.
What pediatric and swallowing-friendly formulation opportunities exist?
The FDA approved AUGTYRO for adult and adolescent patients with ROS1-positive metastatic NSCLC and for patients with NTRK gene fusion-positive solid tumors in specified settings.[2] Pediatric use creates a formulation opportunity because adolescents and younger patients may have difficulty swallowing large capsules, particularly when the regimen requires two 160 mg capsules twice daily after the initial treatment period.
Potential dosage forms include:
- Sprinkle capsules that can be opened onto soft food.
- Oral granules or multiparticulates.
- Powder for oral suspension.
- Mini-tablets.
- Taste-masked oral liquids.
- Lower-strength capsules that allow dose titration by body weight.
A pediatric product would need to address dose accuracy, taste, physical stability, content uniformity, and administration with food or liquids. A multiparticulate product could provide more flexible dosing than a liquid while reducing the risk of sedimentation and preservative-related issues.
The commercial value of pediatric reformulation depends on the size of the eligible population and whether the product gains regulatory exclusivity or meaningful differentiation. A new dosage form may receive separate patent protection if it contains a novel composition, manufacturing process, or administration method. A simple capsule-to-liquid conversion, however, may face a narrower protection window if the underlying formulation is obvious and the API estate remains the principal barrier.
What manufacturing and excipient supply barriers affect AUGTYRO?
The current excipients are broadly available from multiple qualified suppliers. That reduces single-source risk but does not eliminate manufacturing exposure. Critical controls include:
- Lactose particle-size distribution.
- Microcrystalline cellulose bulk density.
- Sodium lauryl sulfate purity and residual impurities.
- Colloidal silicon dioxide flow behavior.
- Magnesium stearate fatty-acid profile and lubrication strength.
- Capsule-shell moisture and mechanical integrity.
- Blend uniformity at the lower 40 mg strength.
Magnesium stearate is particularly important because excessive lubrication can reduce tablet hardness or delay dissolution. In a capsule product, the risk shifts toward powder flow, segregation, fill-weight variation, and capsule-body adhesion.
Excipient manufacturers can compete through pharmaceutical-grade consistency, regional inventory, low-endotoxin grades, regulatory documentation, and validated alternative supply. A supplier with a qualified global network can create value without changing the approved composition. In this setting, the commercial opportunity is more likely to be a strategic supply agreement than an exclusive formulation license.
What patents protect AUGTYRO and its excipient opportunities?
The main intellectual-property risk is expected to arise from repotrectinib composition-of-matter, therapeutic-use, formulation, and manufacturing patents rather than from ownership of common excipients.
The FDA approved repotrectinib under NDA 217664 in November 2023.[2] AUGTYRO is listed in the FDA Orange Book, which is the controlling public source for listed patents, expiration dates, and applicable submission certifications.[3] The precise patent estate must be reviewed against the current Orange Book entry and the latest USPTO records because listing status, pediatric extensions, terminal disclaimers, and patent corrections can change the effective launch analysis.
For excipient developers, the key legal distinctions are:
| IP category | Relevance to an alternative excipient strategy |
|---|---|
| Composition-of-matter patent | Usually the strongest barrier; affects all repotrectinib products |
| Salt, polymorph, or crystal-form patent | Can constrain API sourcing and solid-state selection |
| Formulation patent | May cover a specific excipient combination, particle size, or dissolution profile |
| Method-of-use patent | Can affect indications, dosing schedules, or patient subsets |
| Manufacturing patent | May cover API synthesis, purification, or a finished-product process |
| Capsule or sprinkle patent | May protect differentiated administration formats |
| Trade secret | May cover processing parameters, blend order, and scale-up controls |
An excipient substitution can reduce exposure to a formulation claim, but it generally does not avoid composition-of-matter or method-of-use rights. A generic applicant would still need to address FDA exclusivity, Orange Book patents, Paragraph IV certifications, and any litigation before commercial launch.
When does AUGTYRO lose exclusivity?
AUGTYRO received FDA approval on November 15, 2023.[2] The product received orphan-drug designation for NTRK fusion-positive solid tumors, which may provide seven years of orphan-drug exclusivity for the qualifying indication under the Federal Food, Drug, and Cosmetic Act.[4] The commercial impact of that exclusivity is indication-specific and does not necessarily block every abbreviated application for every use of repotrectinib.
The product also benefits from the standard new-chemical-entity exclusivity framework, generally five years from approval, subject to Paragraph IV timing rules.[5] Because the approval date was in late 2023, a conventional ANDA pathway would face the five-year NCE restriction before submission, with limited exceptions for Paragraph IV patent challenges.
A reliable launch date cannot be derived from approval date alone. The operative analysis requires:
- Current Orange Book patent listings.
- Patent expiration dates.
- Any pediatric exclusivity.
- Orphan exclusivity by indication.
- Litigation triggered by Paragraph IV notices.
- Settlement terms.
- The scope of each proposed generic label.
What is the FDA regulatory status of AUGTYRO?
AUGTYRO is FDA-approved for:
- ROS1-positive locally advanced or metastatic NSCLC.
- NTRK gene fusion-positive locally advanced or metastatic solid tumors in patients who have progressed after prior treatment or have no satisfactory alternative therapy.[1,2]
The drug is administered orally. The recommended regimen begins at 160 mg once daily for 14 days, followed by 160 mg twice daily, subject to dose modification for adverse reactions and drug interactions.[1]
The regimen creates commercial importance for dose flexibility. A formulation that cannot reliably deliver the initial once-daily phase and the subsequent twice-daily phase would have limited clinical utility. Products with 40 mg units may have an advantage for dose reductions, but a lower-strength product can increase manufacturing complexity and packaging requirements.
Which companies are positioned to challenge AUGTYRO?
The most credible challengers are likely to include:
- Generic manufacturers with oncology capsule capabilities.
- Specialty generic companies experienced in Paragraph IV litigation.
- Regional manufacturers seeking repotrectinib rights outside the United States.
- Innovator or specialty-pharma companies developing next-generation TRK or ROS1 inhibitors.
- Contract development and manufacturing organizations with multiparticulate or oral-liquid platforms.
A generic capsule using lactose, microcrystalline cellulose, surfactant, silicon dioxide, and magnesium stearate would probably compete on cost and timing. A differentiated product using a sprinkle, suspension, or pediatric format would compete on administration and market access rather than on simple substitution.
No biosimilar pathway applies. Repotrectinib is a chemically synthesized small molecule, not a biologic. The relevant U.S. pathways are an ANDA, a 505(b)(2) application for a materially different formulation or route, or a full NDA for a new clinical profile.
How strong is the AUGTYRO patent estate?
The patent estate is likely strongest at the API and therapeutic-use levels and weaker at the level of common excipient selection. A competitor that changes lactose to mannitol or replaces sodium lauryl sulfate may avoid a narrow formulation claim, but that change does not neutralize the central API patent position.
Patent strength should be assessed across four questions:
- Does the claim cover repotrectinib itself or only a selected formulation?
- Does the claim cover all clinically relevant ROS1 and NTRK uses?
- Does the claim survive an obviousness challenge based on earlier kinase inhibitors?
- Can a generic product launch with a carve-out label?
A formulation license is most valuable when it provides a non-infringing pediatric or swallowing-friendly product, not merely access to standard excipients. Commercial diligence should separate patent claims covering the drug substance from claims covering the finished dosage form.
What commercial opportunities exist for excipient suppliers?
The opportunity is moderate for commodity excipient suppliers and higher for specialty formulation developers.
Commodity supply opportunities
Suppliers can compete for:
- Pharmaceutical-grade lactose.
- Low-moisture microcrystalline cellulose.
- Controlled-particle-size silicon dioxide.
- High-purity sodium lauryl sulfate.
- Consistent magnesium stearate.
- Capsule shells and printing systems.
The principal purchasing criteria are quality consistency, dual sourcing, regional supply, change-control discipline, and support for regulatory filings.
Higher-value formulation opportunities
The strongest opportunities include:
- A lactose-free AUGTYRO-compatible capsule.
- A low-dose capsule for dose modification.
- A sprinkle formulation for swallowing-impaired patients.
- A pediatric multiparticulate product.
- A moisture-resistant presentation for tropical markets.
- A 505(b)(2) oral suspension with validated dose accuracy.
- A manufacturing process that improves content uniformity and reduces waste.
A differentiated product must show a clinical or operational advantage. A simple excipient swap is unlikely to justify premium pricing unless it solves a documented intolerance, stability problem, supply risk, or administration barrier.
How does AUGTYRO compare with competing targeted therapies?
AUGTYRO competes with other targeted treatments in ROS1-positive NSCLC and NTRK-driven tumors, including crizotinib, entrectinib, larotrectinib, and other kinase inhibitors depending on indication and line of therapy. Its formulation strategy is conventional relative to many oncology products.
| Product | Active ingredient | Primary relevant biomarker | Dosage-form opportunity |
|---|---|---|---|
| AUGTYRO | Repotrectinib | ROS1, NTRK | Capsule, pediatric or sprinkle reformulation |
| XALKORI | Crizotinib | ROS1 and other kinase targets | Capsule and oral solution experience |
| ROZLYTREK | Entrectinib | ROS1, NTRK | Capsule and oral-pellet/oral-liquid development potential |
| VITRAKVI | Larotrectinib | NTRK | Oral solution creates a pediatric benchmark |
| Other ROS1 inhibitors | Various | ROS1 | Differentiation through CNS activity, dosing, or formulation |
Larotrectinib’s oral solution establishes that liquid delivery can be commercially relevant in NTRK-positive populations. That does not establish bioequivalence for repotrectinib, but it supports development of administration-friendly products where pediatric or dysphagia demand is sufficient.
What generic launch risks exist for AUGTYRO?
Generic launch risk is low in the near term because the product has recent approval, NCE exclusivity, orphan-designated indications, and likely patent protection around repotrectinib. Risk increases over time as:
- NCE exclusivity expires.
- Patent challenges become procedurally available.
- Third-party formulators develop alternative dosage forms.
- Patent settlements create a defined authorized or licensed entry date.
- API suppliers establish non-infringing manufacturing routes.
- Clinical use expands enough to support multiple manufacturers.
The most plausible first entrants are likely to use a conventional capsule with a near-match excipient profile. A liquid or sprinkle product may arrive later because it requires more formulation work and may use a 505(b)(2) strategy rather than a standard ANDA.
What licensing deals could create value around AUGTYRO excipients?
Potential licensing structures include:
- BMS licensing a pediatric formulation from a specialty developer.
- An excipient supplier providing a locked formulation platform with regional rights.
- A generic company acquiring a 505(b)(2) dossier for an oral suspension.
- A CDMO partnering with a manufacturer on multiparticulate production.
- A regional licensee receiving rights to a lower-cost capsule presentation.
- A supply agreement with dual-source qualification and volume commitments.
The most defensible deal would combine formulation know-how, process controls, regulatory support, and patent rights. A license based only on standard excipients would have limited bargaining power.
Key Takeaways
- AUGTYRO uses a conventional immediate-release hard-capsule excipient system.
- The primary excipients are lactose monohydrate, microcrystalline cellulose, sodium lauryl sulfate, colloidal silicon dioxide, and magnesium stearate.
- The largest commercial opportunity is a pediatric, sprinkle, multiparticulate, or oral-liquid formulation.
- Excipient substitution can address lactose, stability, supply, or administration issues but does not avoid repotrectinib composition-of-matter patents.
- AUGTYRO has FDA approval for ROS1-positive NSCLC and specified NTRK fusion-positive solid tumors.
- No biosimilar pathway applies because repotrectinib is a small molecule.
- Generic competition will depend on NCE exclusivity, Orange Book patents, Paragraph IV activity, litigation, and possible settlement dates.
- Commodity excipient supply is competitive; specialized formulation development offers higher margins and stronger differentiation.
FAQs
Can AUGTYRO be reformulated without lactose?
Yes. A developer could evaluate mannitol, microcrystalline cellulose, dibasic calcium phosphate, or other pharmaceutical fillers. The replacement must preserve content uniformity, dissolution, stability, and bioequivalence.
Is there an oral liquid version of repotrectinib?
The marketed FDA-approved AUGTYRO product is a capsule. An oral liquid or multiparticulate product would require separate formulation and regulatory development.
Does AUGTYRO require a solubility-enhancing excipient?
The approved label does not establish that a specialized solubility-enhancement platform is required. The commercial formulation uses conventional excipients, although particle engineering and wetting control remain important development variables.
Could a generic manufacturer use the same AUGTYRO excipients?
Potentially, subject to ANDA requirements, patent certification, bioequivalence, product quality, and any applicable formulation claims. Using the same excipient classes does not by itself establish freedom to operate.
Is an AUGTYRO pediatric formulation commercially attractive?
It can be attractive where swallowing difficulty, dose flexibility, or adolescent and pediatric adherence creates a meaningful clinical need. The strongest candidates are sprinkle capsules, multiparticulates, mini-tablets, and accurately dosed oral suspensions.
References
-
Bristol Myers Squibb. (2024). AUGTYRO (repotrectinib) prescribing information. U.S. Food and Drug Administration.
-
U.S. Food and Drug Administration. (2023, November 15). FDA approves repotrectinib for ROS1-positive metastatic non-small cell lung cancer. https://www.fda.gov/
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda
-
U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity. https://www.fda.gov/industry/designating-orphan-product-drugs
-
U.S. Food and Drug Administration. (2024). Small business and industry assistance: New chemical entity exclusivity. https://www.fda.gov/drugs/development-resources/505b2-approval-pathway
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
Visit the Subscription Options page for details on plans and pricing.
ISSN: 2162-2639

Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Access the Complete Database
Deeper Knowledge, Faster
- Identify first generic entrants
- Uncover prior art in expired and abandoned patents
- Obtain formulation and manufacturing information